English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

DOI:10.14744/bej.2017.14633 Beyoglu Eye J 2017; 2(3): 90-95 Original Article Ahmet et al., Polypoidal Choroidal Vasculopathy, Anti-VEGF 91 network vaso-occlusion and polyps, it can be harmful to the physiological choriocapillary layer beyond the irradiated area, and repeated sessions of PDT result in persistent choriocapillary nonperfusion. The rationale for anti-VEGF treatment in PCV is based on the demonstration of VEGF expression in the aqueous humor of patients with PCV. Intravitreally injected anti-VEGF agents reduce the exudation and leakage from the vascular network and polyps. However, it has been demonstrated that the effect of anti-VEGF treatment alone on the regression of polyps was limited. Hence, combination therapy can exert synergistic effects on regressing polyps and better maintain visual acuity (VA) and retinal morphology when compared with PDT or anti-VEGF monotherapy (6). The aim of this study was to evaluate the 2-year outcomes of intravitreal ranibizumab (IVR) therapy in combination with PDT in patients with PCV.

beyoğlu eye journal (online)/beyoğlu eye journal

Two-Year Results of Photodynamic Therapy Combined with Intravitreal Anti-Vascular Endothelial Growth Factor for Polypoidal Choroidal Vasculopathy; A Real Life Experience